BridgeBio Pharma, Inc. (NASDAQ: BBIO) director Jennifer E. Cook has completed a significant reduction in her equity holdings, selling 39,363 shares of the company's common stock for a total aggregate value of $2,752,269. The divestment activity unfolded across two consecutive trading days in June 2026, specifically on June 23 and June 24.
On June 23, Ms. Cook initiated the transaction sequence by disposing of 2,196 shares at a price point of $68.57 per share. The subsequent day, June 24, saw the bulk of the sales activity, where she offloaded an additional 37,167 shares at a price of $70.00 per share. The pricing for these transactions ranged from $68.57 to $70.00 per share. These sales were executed pursuant to a Rule 10b5-1 sales plan, which Ms. Cook originally adopted on March 16, 2026. This structured plan allows for the pre-arranged sale of securities independent of internal market timing decisions.
Concurrent with the sales activity, Ms. Cook engaged in share acquisition through the exercise of stock options on June 24. She acquired 20,000 shares at an exercise price of $8.45 per share and an additional 17,167 shares at an exercise price of $16.75 per share. The total value derived from these option exercises amounted to $456,547. Furthermore, on June 22, Ms. Cook was granted 3,990 restricted stock units (RSUs) at a price of $0.00. Each RSU represents a contingent right to receive one share of common stock, with full vesting scheduled for June 22, 2027, contingent upon her continued service on the board. On the same date, she received a grant of 5,277 stock options with an exercise price of $68.92 per share, set to expire on June 21, 2036, also vesting in full on June 22, 2027, subject to continued board service.
Following these reported transactions, Jennifer E. Cook directly holds 8,383 shares of BridgeBio Pharma common stock. The insider activity comes as BridgeBio shares currently trade at $69.36, delivering a remarkable 56% return over the past year. According to InvestingPro analysis, the stock appears slightly overvalued relative to its Fair Value. For deeper insights into BBIO’s valuation and comprehensive analysis—including exclusive ProTips and detailed financial health metrics—investors can access the full Pro Research Report, available for this and 1,400+ other US equities.
In related corporate developments, BridgeBio Pharma has received FDA Priority Review status for its new drug application for BBP-418, an oral treatment for limb-girdle muscular dystrophy type 2I/R9. The FDA has set a target action date of November 27, 2026, for this application. Additionally, BridgeBio is set to present data from its Phase 3 study of oral infigratinib in children with achondroplasia at the International Congress of Children’s Bone Health. The presentation will be delivered by Dr. Ravi Savarirayan, the Global Lead Investigator for the study.
Market sentiment regarding the company has seen shifts from financial institutions. Mizuho has made adjustments to its outlook on BridgeBio Pharma, lowering the stock price target from $106 to $96 due to concerns over the company’s balance sheet, specifically regarding $550 million in convertible notes due in 2027. Despite this, Mizuho maintains an Outperform rating, highlighting BridgeBio’s likely graduation to the Russell 1000 index due to its market cap. On the other hand, Raymond James has downgraded BridgeBio to Market Perform from Outperform, citing increasing payer-driven risks as a challenge. These developments provide investors with a range of insights into BridgeBio Pharma’s current position and future prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.Should you invest $2,000 in BBIO right now?ProPicks AI evaluates BBIO alongside thousands of other companies every month using 100+ financial metrics. Using powerful AI to generate exciting stock ideas, it looks beyond popularity to assess fundamentals, momentum, and valuation. The AI has no bias—it simply identifies which stocks offer the best risk-reward based on current data with notable past winners that include Super Micro Computer (+185%) and AppLovin (+157%). Want to know if BBIO is currently featured in any ProPicks AI strategies, or if there are better opportunities in the same space?See More Stocks